CHMP recommends approval of the new base is based on the triple therapy of Revlidomide (Lenalidomide, Tonala)

recently, Celgenecompany(http:// announcedthat the European EMA humanmedicine(http://product(http://Committee (CHMP) recommended that the company's triple therapy based on Revlimid (Lenalidomide), approved for untreated and unsuitable for multiple myeloma patients (MMMs) who have received stem cell transplant therapyat the same time, CHMP recommended triple therapy based on Immalidomide (pomalidomide, Pomadomide) for MM patients who have received at least one pre-treatment, including lenalidomideThe EU is expected to make a final decision within two monthsBoth The chemotherapythe
http:// developed by New Base, areof the chemotherapythe drug http:// both of which are derivatives of thalidomideIt has the effect of anti-vascular hyperplasia, and immune regulation They have been approved for the treatment of recurrent/incurable MM patients and are constantly expanding the range of indications the combination of the two combinations of leamine and dexamethasone plus bortezomib (RVd) and Pomadoamine and dexamethason plus bortzozomi (PVd) therapy If approved by the European Union, it would be the first time the two combination therapies have been approved worldwide 　　CHMP's support for RVd therapy is based on the results of phase 3 clinical trial (http:// called SWOG S0777 The results showed that patients treated with RVd combination therapy had significantly increased progression and total survival compared to the patients receiving the combination therapy (Rd) of the nalaa and dexamethasone The choice of first-line therapy is important because as the patient's disease progresses, their response to the treatment gets worse and the relief period gets shorter and shorter